Tanezumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | NGF |
| Clinical data | |
| Synonyms | RN624 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6464H9942N1706O2026S46 |
| Molar mass | 145.4 kg/mol |
  (what is this?) (verify) | |
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.[1]
In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).[2] Another Phase III trial for hip pain in OA [3] was halted in June 2010 when some patients needed hip replacement.[4]
Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.[5]
In March of 2012, the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.[6] [7]
A Phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.[8]
References
- ↑ N05, American Medical Association.
- ↑ "Tanezumab in Osteoarthritis of the Knee". 2009
- ↑ "Tanezumab in Osteoarthritis Of The Hip".
- ↑ http://www.genengnews.com/gen-news-highlights/trials-halted-as-pfizer-s-tanezumab-shown-to-worsen-osteoarthritis/81243572/
- ↑ "Phase II trials involving Tanezumab".
- ↑ http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM295205.pdf
- ↑ http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm301305.pdf
- ↑ "Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.". Arthritis Rheum. 65: 1795–803. Jul 2013. PMID 23553790. doi:10.1002/art.37950.